A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
What is the purpose of this trial?
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Trial withNextCure, Inc.
- Start Date05/06/2019
- End Date08/31/2020
- Last Updated06/18/2019
- Study HIC#2000023979